Escitalopram treatment of depression in human immunodeficiency virus/acquired immunodeficiency syndrome: A randomized, double-blind, placebo-controlled study

Journal of Nervous and Mental Disease

Volumn 202, Issue 2, 2014, Pages 133-137

  Hoare, Jacqueline ^a   Carey, Paul ^b   Joska, John A ^a   Carrara, Henri ^a   Sorsdahl, Katherine ^a   Stein, Dan J ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF STELLENBOSCH   (South Africa)

Author keywords

Depression; HIV; Randomized controlled study

Indexed keywords

ESCITALOPRAM; PLACEBO;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MIDDLE AGED; NAUSEA AND VOMITING; PLACEBO EFFECT; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SINGLE BLIND PROCEDURE; TREATMENT DURATION; YOUNG ADULT;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84893509517     PISSN: 00223018     EISSN: 1539736X     Source Type: Journal    
DOI: 10.1097/NMD.0000000000000082     Document Type: Article

References (45)

1. Bekker LG, Myer L, Wood R (2006) Impact of HIV Infection on the Epidemiology of Tuberculosis in a Peri-Urban Community in South Africa: The Need for Age-Specific Interventions. Clin Infect Dis. 42:1040-1047.
2. Berghuis JP, Uldall KK, Lalonde B (1999) Validity of two scales in identifying HIV-associated dementia. J Acquir Immune Defic Syndr. 21:134-140.
3. Brosen K, Naranjo CA (2001) Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. Eur Neuropsychopharmacol. 11:275-283.
4. Burke WJ, Gergel I, Bose A (2002) Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry. 63:331-336.
5. Caballero J, Nahata MC (2004) Use of selective serotonin-reuptake inhibitors in the treatment of depression in adults with HIV. Ann Pharmacother. 30:1065.
6. Carey PD, Stein DJ, Zungu-Dirwayi N, Seedat S (2003) Trauma and posttraumatic stress disorder in an urban Xhosa primary care population: Prevalence, comorbidity, and service use patterns. J Nerv Ment Dis. 191:230-236.
7. Ciesla JA, Roberts JE (2001) Meta-analysis of the relationship between HIV infection and risk for depressive disorders. Am J Psychiatry. 158:725-730.
8. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, Watanabe N, Nakagawa A, Omori IM, McGuire H, Tansella M, Barbui C (2009) Comparative efficacy and acceptability of 12 new-generation antidepressants: A multiple-treatments meta-analysis. Lancet. 373:746-758.
9. Cockram A, Judd FK, Mijch A, Norman T (1999) The evaluation of depression in inpatients with HIV disease. Aust N Z J Psychiatry. 33:344-352.
10. Cohen RA, Harezlak J, Schifitto G, Hana G, Clark U, Gongvatana A, Paul R, Taylor M, Thompson P, Alger J, Brown M, Zhong J, Campbell T, Singer E, Daar E, McMahon D, Tso Y, Yiannoutsos CT, Navia B (2010) Effects of nadir CD4 count and duration of human immunodeficiency virus infection on brain volumes in the highly active antiretroviral therapy era. J Neurovirol. 16:25-32.
11. Elliott AJ, Uldall KK, Bergam K, Russo J, Claypoole K, Roy-Byrne PP (1998) Randomized, placebo-controlled trial of paroxetine versus imipramine in depressed HIV-positive outpatients. Am J Psychiatry. 155:367-372.
12. Evans DL, Staab J, Ward H, Leserman J, Perkins DO, Golden RN, Petitto JM (1996) Depression in the medically ill: Management considerations. Depress Anxiety. 4:199-208.
13. Fairfield KM, Libman H, Davis RB, Eisenberg DM (1999) Delays in protease inhibitor use in clinical practice. J Gen Intern Med. 14:395-401.
14. Ferrando SJ, Freyberg Z (2008) Treatment of depression in HIV positive individuals: A critical review. Int Rev Psychiatry. 20:61-71.
15. Folstein MF, Folstein SE, McHugh PR (1975) ''Mini-mental state''. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 12:189-198.
16. Gabryelewicz T, Styczynska M, Pfeffer A, Wasiak B, Barczak A, Luczywek E, Androsiuk W, Barcikowska M (2004) Prevalence of major and minor depression in elderly persons with mild cognitive impairmentVMADRS factor analysis. Int J Geriatr Psychiatry. 19:1168-1172.
17. Gordillo V, del AJ, Soriano V, Gonzalez-Lahoz J (1999) Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS. 13:1763-1769.
18. Gorman JM, Korotzer A, Su G (2002) Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: Pooled analysis of placebo-controlled trials. CNS Spectr. 7:40-44.
19. Gutierrez MM, Rosenberg J, Abramowitz W (2003) An evaluation of the potential for pharmacokinetic interaction between escitalopram and the cytochrome P450 3A4 inhibitor ritonavir. Clin Ther. 25:1200-1210.
20. Guy W (1976) ECDU assessment manual for psychopharmacology. Rockville: National Institute of Mental Health, Research Branc.h.
21. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry. 23:56-62.
22. Horberg M, Silverberg M, Hurley L, Delorenze G, Quesenberry C (2008) Influence of prior antiretroviral experience on adherence and responses to new highly active antiretroviral therapy regimens. AIDS Patient Care STDS. 22:301-312.
23. Ickovics JR, Hamburger ME, Vlahov D, Schoenbaum EE, Schuman P, Boland RJ, Moore J (2001) Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: Longitudinal analysis from the HIV Epidemiology Research Study. JAMA. 285:1466-1474.
24. Jacobsberg LB, Perry S (1992) Medical management of AIDS patients. Psychiatric disturbances. Med Clin North Am. 76:99-106.
25. Kagee A, Remien RH, Berkman A, Hoffman S, Campos L, Swartz L (2011) Structural barriers to ART adherence in Southern Africa: challenges and potential ways forward. Glob Public Health. 6:83-97.
26. Kalichman SC, Rompa D, Cage M (2000) Distinguishing between overlapping somatic symptoms of depression and HIV disease in people living with HIVAIDS. J Nerv Ment Dis. 188:662-670.
27. Leentjens AF, Marinus J, Van Hilten JJ, Lousberg R, Verhey FR (2003) The contribution of somatic symptoms to the diagnosis of depressive disorder in Parkinson's disease: A discriminant analytic approach. J Neuropsychiatry Clin Neurosci. 15:74-77.
28. Leentjens AF, Verhey FR, Lousberg R, Spitsbergen H, Wilmink FW (2000) The validity of the Hamilton and Montgomery-Asberg depression rating scales as screening and diagnostic tools for depression in Parkinson's disease. Int J Geriatr Psychiatry. 15:644-649.
29. Lepola UM, Loft H, Reines EH (2003) Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol. 18:211-217.
30. Leserman J, Jackson ED, Petitto JM, Golden RN, Silva SG, Perkins DO, Cai J, Folds JD, Evans DL (1999) Progression to AIDS: The effects of stress, depressive symptoms, and social support. Psychosom Med. 61:397-406.
31. Montgomery SA, Asberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry. 134:382-389.
32. Nattrass N (2006) Trading off income and health?: AIDS and the disability grant in South Africa. J Soc Policy. 35:3-19.
33. Olley BO, Seedat S, Stein DJ (2004) Psychopathology and coping in recently diagnosed HIV/AIDS patients. S Afr Med J. 94:720, 722.
34. Owens MJ, Knight DL, Nemeroff CB (2001) Second-generation SSRIs: Human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry. 50:345-350.
35. Pappin M, Wouters E, Booysen F (2012) Anxiety and depression amongst patients enrolled in a public sector antiretroviral treatment programme in South Africa: a cross-sectional study. BMC Public Health. 12:244.
36. Power C, Selnes OA, Grim JA, McArthur JC (1995) HIV Dementia Scale: A rapid screening test. J Acquir Immune Defic Syndr Hum Retrovirol. 8: 273-278.
37. Rabkin JG, Wagner GJ, Rabkin R (1999) Fluoxetine treatment for depression in patients with HIV and AIDS: A randomized, placebo-controlled trial. Am J Psychiatry. 156:101-107.
38. Savard J, Laberge B, Gauthier JG, Ivers H, Bergeron MG (1998) Evaluating anxiety and depression in HIV-infected patients. J Pers Assess. 71:349-367.
39. Sheehan DV (1983) The anxiety disease. New York: Scribner.s.
40. Stein DJ, Baldwin DS, Dolberg OT, Despiegel N, Bandelow B (2006) Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of escitalopram. J Clin Psychiatry. 67:1741-1746.
41. von Moltke LL, Greenblatt DJ, Giancarlo GM, Granda BW, Harmatz JS, Shader RI (2001) Escitalopram (S-citalopram) and its metabolites in vitro: Cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab Dispos. 29:1102-1109.
42. Wade A, Michael LO, Bang HK (2002) Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol. 17:95-102.
43. Walker Z, Walker RW, Robertson MM, Stansfeld S (1998) Antidepressant treatment of chronic tension-type headache: A comparison between fluoxetine and desipramine. Headache. 38:523-528.
44. Zigmond AS, Snaith RP (1983) The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 67:361-370.
45. Zisook S, Peterkin J, Goggin KJ, Sledge P, Atkinson JH, Grant I (1998) Treatment of major depression in HIV-seropositive men. HIV Neurobehavioral Research Center Group. J Clin Psychiatry. 59:217-224.